Development of novel G protein coupled receptor assay systems for bioactive compound monitoring
Project is carried out within the European Regional Development Fund (ERDF) activity "Support for science and research"
Project identification no: 2010/0310/2DP/18.104.22.168.0/10/APIA/VIAA/069
Project activity period: 36 months (01.01.2011.-31.12.2013.)
Projekta kopējais finansējums: 284 419,00 LVL
Principle investigator: Dr. biol. Jānis Kloviņš
General aim of the project – elaboration of novel product and improving existing technology of the G-protein coupled receptor therapeutically active ligand screening and pharmacological testing based on the recombinant mammalian and yeast cell systems, which will increase pharmaceutical industry competitiveness and export in Latvia..
Specific aim of the project – development of human adrenocorticotropic hormone (MC2) and GPR119 receptors recombinant expression systems in yeast and mammalian cells for efficient active ligand screening and development of MC2 and GPR119 receptors functional test prototypes and GPCR active ligand screening service.
In order to achieve the project goals, following activities are planned to be accomplished within the project:
1.1. Industrial research
This activity will be performed with an aim to 1) generate MC2 and GPR119 receptor recombinant constructs for receptors expression in transformed yeast and mammalian cells; 2) generate eukaryotic cell lines expressing human MC2R and GPR119; 3) validate cells and method for receptors active ligand screening.
1.2. Experimental development:
Development of the human MC2R and GPR119 pharmacological and functional assay prototypes for commercial purpose and GPCRs active ligand pharmacological screening service.
2. Ensuring of public assessment to the study results.
3. Consolidation of industrial property rights for the study results.